143 related articles for article (PubMed ID: 21560524)
1. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
[TBL] [Abstract][Full Text] [Related]
2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
3. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
Louhimo J; Alfthan H; Stenman UH; Haglund C
Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
[TBL] [Abstract][Full Text] [Related]
4. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
7. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
Klapdor R; Bahlo M; Babinsky A
Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer and tumor markers: role of the newly identified CAR-3 antigen.
Giulianotti PC; Boggi U; Ferdeghini M; Di Candio G; Caravaglios G; Bellini R; Mosca F
Ann Ital Chir; 1997; 68(3):307-13. PubMed ID: 9419908
[TBL] [Abstract][Full Text] [Related]
11. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
12. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
13. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
14. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
15. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
16. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
17. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.
Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH
J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630
[TBL] [Abstract][Full Text] [Related]
18. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
19. Atypical courses of serum tumor markers--4 case reports.
Klapdor R; Bahlo M; Babinski A
Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of serum tumor markers in asymptomatic individuals.
Eleftheriadis N; Papaloukas C; Pistevou-Gompaki K
J BUON; 2009; 14(4):707-10. PubMed ID: 20148467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
